-X 003044-8
IPOS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 471/04, A61K 31/435, C07D 487/04 // (C07D 471/04, 221:00, 209:00) (C07D 487/04, 209:00, 209:00) (C07D 487/04, 223:00, 209:00)

A1

(11) International Publication Number: **WO 98/14447**

(43) International Publication Date: 9 April 1998 (09.04.98)

(21) International Application Number: PCT/DK97/00418

(22) International Filing Date: 1 October 1997 (01.10.97)

(30) Priority Data:

1069/96	1 October 1996 (01.10.96)	DK
1277/96	13 November 1996 (13.11.96)	DK

(71) Applicant *(for all designated States except US)*: NEUROSEARCH A/S [DK/DK]; Smedeland 26B, DK-2600 Glostrup (DK).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: WÄTJEN, Frank [DK/DK]; NeuroSearch a/s, Smedeland 26 B, DK-2600 Glostrup (DK). DREJER, Jørgen [DK/DK]; NeuroSearch a/s, Smedeland 26 B, DK-2600 Glostrup (DK).

(74) Common Representative: NEUROSEARCH A/S; Smedeland 26 B, DK-2600 Glostrup (DK).


(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: NOVEL INDOLE-2,3-DIONE-3-OXIME DERIVATIVES



(I)



(II)

(57) Abstract

The present invention relates to novel indole-2,3-dione-3-oxime derivatives capable of antagonising the effect of excitatory amino acids, such as glutamate. More specifically the novel indole-2,3-dione-3-oxime derivatives of the invention may be described by general formula (I), wherein R^3 represents "Het", or a group of formula (II), wherein "Het" represents a saturated or unsaturated, 4 to 7 membered, monocyclic, heterocyclic ring, at least one of R^{31}, R^{32}, and R^{33} independently represents hydrogen, alkyl, or hydroxyalkyl, and at least one of R^{31}, R^{32}, and R^{33} independently represents $(CH_2)_nR^{34}$; wherein R^{34} represents hydroxy, carboxy, alkoxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, cycloalkoxycarbonyl, cycloalkyl-alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, $CONR^{35}R^{36}$, or "Het"; wherein n is 0, 1, 2, or 3; and R^5 represents phenyl, naphthyl, thienyl, or pyridyl, all of which may be substituted. "A" represents a ring of five to seven atoms fused with the benzo ring at the positions marked "a" and "b", and formed by the following bivalent radicals: a-NR^6-CH_2-CH_2-b; a-CH_2-NR^6-CH_2-b; a-CH_2-CH_2-NR^6-b; a-NR^6-CH_2-CH_2-CH_2-b; a-CH_2-NR^6-CH_2-CH_2-b; a-CH_2-CH_2-NR^6-CH_2-b; a-CH_2-CH_2-CH_2-NR^6-b; a-NR^6-CH_2-CH_2-CH_2-CH_2-b; a-CH_2-NR^6-CH_2-CH_2-CH_2-b; a-CH_2-CH_2-NR^6-CH_2-CH_2-b; a-CH_2-CH_2-CH_2-NR^6-CH_2-b; or a-CH_2-CH_2-CH_2-CH_2-NR^6-b; wherein R^6 represents hydrogen, alkyl or CH_2CH_2OH; or a pharmaceutically acceptable salt thereof.